Does the media prefer NVO or JNJ?

In the previous week, Novo Nordisk A/S had 19 more articles in the media than Johnson & Johnson. MarketBeat recorded 80 mentions for Novo Nordisk A/S and 61 mentions for Johnson & Johnson. Johnson & Johnson's average media sentiment score of 0.99 beat Novo Nordisk A/S's score of 0.38 indicating that Johnson & Johnson is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novo Nordisk A/S 27 Very Positive mention(s) 20 Positive mention(s) 13 Neutral mention(s) 11 Negative mention(s) 6 Very Negative mention(s) Neutral Johnson & Johnson 42 Very Positive mention(s) 8 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Which has higher valuation & earnings, MRK or NVO?

Merck & Co., Inc. has higher revenue and earnings than Novo Nordisk A/S. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Merck & Co., Inc. $65.01B 4.96 $18.25B $1.25 104.37 Novo Nordisk A/S $46.80B 4.50 $15.51B $4.09 11.54

Does the media prefer MRK or NVO?

In the previous week, Novo Nordisk A/S had 26 more articles in the media than Merck & Co., Inc.. MarketBeat recorded 80 mentions for Novo Nordisk A/S and 54 mentions for Merck & Co., Inc.. Merck & Co., Inc.'s average media sentiment score of 0.65 beat Novo Nordisk A/S's score of 0.38 indicating that Merck & Co., Inc. is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Merck & Co., Inc. 26 Very Positive mention(s) 5 Positive mention(s) 11 Neutral mention(s) 4 Negative mention(s) 2 Very Negative mention(s) Positive Novo Nordisk A/S 27 Very Positive mention(s) 20 Positive mention(s) 13 Neutral mention(s) 11 Negative mention(s) 6 Very Negative mention(s) Neutral

Is NVO or NVS more profitable?

Novo Nordisk A/S has a net margin of 35.36% compared to Novartis' net margin of 23.29%. Novo Nordisk A/S's return on equity of 61.20% beat Novartis' return on equity. Company Net Margins Return on Equity Return on Assets Novo Nordisk A/S 35.36% 61.20% 21.49% Novartis 23.29% 38.56% 14.47%

Does the media prefer NVO or NVS?

In the previous week, Novo Nordisk A/S had 63 more articles in the media than Novartis. MarketBeat recorded 80 mentions for Novo Nordisk A/S and 17 mentions for Novartis. Novo Nordisk A/S's average media sentiment score of 0.38 beat Novartis' score of 0.31 indicating that Novo Nordisk A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novo Nordisk A/S 27 Very Positive mention(s) 20 Positive mention(s) 13 Neutral mention(s) 11 Negative mention(s) 6 Very Negative mention(s) Neutral Novartis 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer AZN or NVO?

In the previous week, Novo Nordisk A/S had 36 more articles in the media than Astrazeneca. MarketBeat recorded 80 mentions for Novo Nordisk A/S and 44 mentions for Astrazeneca. Astrazeneca's average media sentiment score of 0.67 beat Novo Nordisk A/S's score of 0.38 indicating that Astrazeneca is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Astrazeneca 22 Very Positive mention(s) 4 Positive mention(s) 13 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Positive Novo Nordisk A/S 27 Very Positive mention(s) 20 Positive mention(s) 13 Neutral mention(s) 11 Negative mention(s) 6 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, PFE or NVO?

Novo Nordisk A/S has lower revenue, but higher earnings than Pfizer. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pfizer $62.58B 2.47 $7.77B $0.76 35.61 Novo Nordisk A/S $46.80B 4.50 $15.51B $4.09 11.54

Is PFE or NVO more profitable?

Novo Nordisk A/S has a net margin of 35.36% compared to Pfizer's net margin of 6.80%. Novo Nordisk A/S's return on equity of 61.20% beat Pfizer's return on equity. Company Net Margins Return on Equity Return on Assets Pfizer 6.80% 19.63% 8.46% Novo Nordisk A/S 35.36% 61.20% 21.49%

Does the media refer more to PFE or NVO?

In the previous week, Novo Nordisk A/S had 4 more articles in the media than Pfizer. MarketBeat recorded 80 mentions for Novo Nordisk A/S and 76 mentions for Pfizer. Pfizer's average media sentiment score of 0.45 beat Novo Nordisk A/S's score of 0.38 indicating that Pfizer is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pfizer 25 Very Positive mention(s) 12 Positive mention(s) 25 Neutral mention(s) 11 Negative mention(s) 1 Very Negative mention(s) Neutral Novo Nordisk A/S 27 Very Positive mention(s) 20 Positive mention(s) 13 Neutral mention(s) 11 Negative mention(s) 6 Very Negative mention(s) Neutral

Novo Nordisk A/S (NVO) Competitors

$47.22 -0.04 (-0.07%)

As of 01:06 PM Eastern

Compare

NVO vs. JNJ, MRK, NVS, AZN, and PFE

Should you buy Novo Nordisk A/S stock or one of its competitors? MarketBeat compares Novo Nordisk A/S with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Novo Nordisk A/S include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Novartis (NVS), Astrazeneca (AZN), and Pfizer (PFE). These companies are all part of the "pharmaceuticals" industry.

How does Novo Nordisk A/S compare to Johnson & Johnson?

Novo Nordisk A/S (NYSE:NVO) and Johnson & Johnson (NYSE:JNJ) are both large-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings.

11.5% of Novo Nordisk A/S shares are held by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are held by institutional investors. 0.1% of Novo Nordisk A/S shares are held by insiders. Comparatively, 0.2% of Johnson & Johnson shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Johnson & Johnson has higher revenue and earnings than Novo Nordisk A/S. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novo Nordisk A/S	$46.80B	4.50	$15.51B	$4.09	11.54
Johnson & Johnson	$97.93B	6.40	$26.80B	$8.63	30.14

Novo Nordisk A/S has a net margin of 35.36% compared to Johnson & Johnson's net margin of 21.48%. Novo Nordisk A/S's return on equity of 61.20% beat Johnson & Johnson's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novo Nordisk A/S	35.36%	61.20%	21.49%
Johnson & Johnson	21.48%	32.42%	13.35%

Novo Nordisk A/S has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market. Comparatively, Johnson & Johnson has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market.

Novo Nordisk A/S pays an annual dividend of $1.75 per share and has a dividend yield of 3.7%. Johnson & Johnson pays an annual dividend of $5.36 per share and has a dividend yield of 2.1%. Novo Nordisk A/S pays out 42.8% of its earnings in the form of a dividend. Johnson & Johnson pays out 62.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Johnson & Johnson has raised its dividend for 64 consecutive years. Novo Nordisk A/S is clearly the better dividend stock, given its higher yield and lower payout ratio.

In the previous week, Novo Nordisk A/S had 19 more articles in the media than Johnson & Johnson. MarketBeat recorded 80 mentions for Novo Nordisk A/S and 61 mentions for Johnson & Johnson. Johnson & Johnson's average media sentiment score of 0.99 beat Novo Nordisk A/S's score of 0.38 indicating that Johnson & Johnson is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novo Nordisk A/S	27 Very Positive mention(s)	20 Positive mention(s)	13 Neutral mention(s)	11 Negative mention(s)	6 Very Negative mention(s)	Neutral
Johnson & Johnson	42 Very Positive mention(s)	8 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Novo Nordisk A/S presently has a consensus target price of $65.81, indicating a potential upside of 39.42%. Johnson & Johnson has a consensus target price of $268.22, indicating a potential upside of 3.13%. Given Novo Nordisk A/S's higher probable upside, analysts clearly believe Novo Nordisk A/S is more favorable than Johnson & Johnson.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novo Nordisk A/S	1 Sell rating(s)	15 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.19
Johnson & Johnson	0 Sell rating(s)	6 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

Johnson & Johnson beats Novo Nordisk A/S on 12 of the 20 factors compared between the two stocks.

How does Novo Nordisk A/S compare to Merck & Co., Inc.?

Merck & Co., Inc. (NYSE:MRK) and Novo Nordisk A/S (NYSE:NVO) are both large-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, analyst recommendations, institutional ownership, media sentiment, risk and valuation.

Merck & Co., Inc. has a beta of 0.19, indicating that its share price is 81% less volatile than the broader market. Comparatively, Novo Nordisk A/S has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market.

Novo Nordisk A/S has a net margin of 35.36% compared to Merck & Co., Inc.'s net margin of 4.77%. Novo Nordisk A/S's return on equity of 61.20% beat Merck & Co., Inc.'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Merck & Co., Inc.	4.77%	16.05%	6.11%
Novo Nordisk A/S	35.36%	61.20%	21.49%

76.1% of Merck & Co., Inc. shares are owned by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are owned by institutional investors. 0.2% of Merck & Co., Inc. shares are owned by insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Novo Nordisk A/S had 26 more articles in the media than Merck & Co., Inc.. MarketBeat recorded 80 mentions for Novo Nordisk A/S and 54 mentions for Merck & Co., Inc.. Merck & Co., Inc.'s average media sentiment score of 0.65 beat Novo Nordisk A/S's score of 0.38 indicating that Merck & Co., Inc. is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Merck & Co., Inc.	26 Very Positive mention(s)	5 Positive mention(s)	11 Neutral mention(s)	4 Negative mention(s)	2 Very Negative mention(s)	Positive
Novo Nordisk A/S	27 Very Positive mention(s)	20 Positive mention(s)	13 Neutral mention(s)	11 Negative mention(s)	6 Very Negative mention(s)	Neutral

Merck & Co., Inc. has higher revenue and earnings than Novo Nordisk A/S. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Merck & Co., Inc.	$65.01B	4.96	$18.25B	$1.25	104.37
Novo Nordisk A/S	$46.80B	4.50	$15.51B	$4.09	11.54

Merck & Co., Inc. presently has a consensus target price of $134.56, indicating a potential upside of 3.14%. Novo Nordisk A/S has a consensus target price of $65.81, indicating a potential upside of 39.42%. Given Novo Nordisk A/S's higher probable upside, analysts plainly believe Novo Nordisk A/S is more favorable than Merck & Co., Inc..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Merck & Co., Inc.	0 Sell rating(s)	7 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.65
Novo Nordisk A/S	1 Sell rating(s)	15 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.19

Merck & Co., Inc. pays an annual dividend of $3.40 per share and has a dividend yield of 2.6%. Novo Nordisk A/S pays an annual dividend of $1.75 per share and has a dividend yield of 3.7%. Merck & Co., Inc. pays out 272.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Novo Nordisk A/S pays out 42.8% of its earnings in the form of a dividend. Merck & Co., Inc. has increased its dividend for 14 consecutive years. Novo Nordisk A/S is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Merck & Co., Inc. beats Novo Nordisk A/S on 10 of the 19 factors compared between the two stocks.

How does Novo Nordisk A/S compare to Novartis?

Novo Nordisk A/S (NYSE:NVO) and Novartis (NYSE:NVS) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Novo Nordisk A/S has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market. Comparatively, Novartis has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market.

In the previous week, Novo Nordisk A/S had 63 more articles in the media than Novartis. MarketBeat recorded 80 mentions for Novo Nordisk A/S and 17 mentions for Novartis. Novo Nordisk A/S's average media sentiment score of 0.38 beat Novartis' score of 0.31 indicating that Novo Nordisk A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novo Nordisk A/S	27 Very Positive mention(s)	20 Positive mention(s)	13 Neutral mention(s)	11 Negative mention(s)	6 Very Negative mention(s)	Neutral
Novartis	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Novo Nordisk A/S pays an annual dividend of $1.75 per share and has a dividend yield of 3.7%. Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.0%. Novo Nordisk A/S pays out 42.8% of its earnings in the form of a dividend. Novartis pays out 46.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novo Nordisk A/S is clearly the better dividend stock, given its higher yield and lower payout ratio.

Novo Nordisk A/S presently has a consensus price target of $65.81, suggesting a potential upside of 39.42%. Novartis has a consensus price target of $141.20, suggesting a potential downside of 9.63%. Given Novo Nordisk A/S's higher possible upside, analysts plainly believe Novo Nordisk A/S is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novo Nordisk A/S	1 Sell rating(s)	15 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.19
Novartis	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.31

11.5% of Novo Nordisk A/S shares are held by institutional investors. Comparatively, 13.1% of Novartis shares are held by institutional investors. 0.1% of Novo Nordisk A/S shares are held by insiders. Comparatively, 0.0% of Novartis shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Novo Nordisk A/S has a net margin of 35.36% compared to Novartis' net margin of 23.29%. Novo Nordisk A/S's return on equity of 61.20% beat Novartis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novo Nordisk A/S	35.36%	61.20%	21.49%
Novartis	23.29%	38.56%	14.47%

Novo Nordisk A/S has higher earnings, but lower revenue than Novartis. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novo Nordisk A/S	$46.80B	4.50	$15.51B	$4.09	11.54
Novartis	$54.53B	5.47	$13.98B	$6.63	23.57

Summary

Novo Nordisk A/S beats Novartis on 11 of the 18 factors compared between the two stocks.

How does Novo Nordisk A/S compare to Astrazeneca?

Astrazeneca (NYSE:AZN) and Novo Nordisk A/S (NYSE:NVO) are both large-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation.

Novo Nordisk A/S has a net margin of 35.36% compared to Astrazeneca's net margin of 17.02%. Novo Nordisk A/S's return on equity of 61.20% beat Astrazeneca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Astrazeneca	17.02%	31.45%	13.20%
Novo Nordisk A/S	35.36%	61.20%	21.49%

Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.7%. Novo Nordisk A/S pays an annual dividend of $1.75 per share and has a dividend yield of 3.7%. Astrazeneca pays out 64.9% of its earnings in the form of a dividend. Novo Nordisk A/S pays out 42.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novo Nordisk A/S is clearly the better dividend stock, given its higher yield and lower payout ratio.

In the previous week, Novo Nordisk A/S had 36 more articles in the media than Astrazeneca. MarketBeat recorded 80 mentions for Novo Nordisk A/S and 44 mentions for Astrazeneca. Astrazeneca's average media sentiment score of 0.67 beat Novo Nordisk A/S's score of 0.38 indicating that Astrazeneca is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Astrazeneca	22 Very Positive mention(s)	4 Positive mention(s)	13 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Positive
Novo Nordisk A/S	27 Very Positive mention(s)	20 Positive mention(s)	13 Neutral mention(s)	11 Negative mention(s)	6 Very Negative mention(s)	Neutral

20.4% of Astrazeneca shares are owned by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are owned by institutional investors. 0.1% of Novo Nordisk A/S shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Astrazeneca presently has a consensus price target of $211.00, indicating a potential upside of 30.23%. Novo Nordisk A/S has a consensus price target of $65.81, indicating a potential upside of 39.42%. Given Novo Nordisk A/S's higher possible upside, analysts clearly believe Novo Nordisk A/S is more favorable than Astrazeneca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astrazeneca	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
Novo Nordisk A/S	1 Sell rating(s)	15 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.19

Astrazeneca has a beta of 0.26, suggesting that its stock price is 74% less volatile than the broader market. Comparatively, Novo Nordisk A/S has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market.

Novo Nordisk A/S has lower revenue, but higher earnings than Astrazeneca. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astrazeneca	$58.74B	4.28	$10.23B	$6.69	24.22
Novo Nordisk A/S	$46.80B	4.50	$15.51B	$4.09	11.54

Summary

Novo Nordisk A/S beats Astrazeneca on 11 of the 18 factors compared between the two stocks.

How does Novo Nordisk A/S compare to Pfizer?

Pfizer (NYSE:PFE) and Novo Nordisk A/S (NYSE:NVO) are both large-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Novo Nordisk A/S has a net margin of 35.36% compared to Pfizer's net margin of 6.80%. Novo Nordisk A/S's return on equity of 61.20% beat Pfizer's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pfizer	6.80%	19.63%	8.46%
Novo Nordisk A/S	35.36%	61.20%	21.49%

In the previous week, Novo Nordisk A/S had 4 more articles in the media than Pfizer. MarketBeat recorded 80 mentions for Novo Nordisk A/S and 76 mentions for Pfizer. Pfizer's average media sentiment score of 0.45 beat Novo Nordisk A/S's score of 0.38 indicating that Pfizer is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pfizer	25 Very Positive mention(s)	12 Positive mention(s)	25 Neutral mention(s)	11 Negative mention(s)	1 Very Negative mention(s)	Neutral
Novo Nordisk A/S	27 Very Positive mention(s)	20 Positive mention(s)	13 Neutral mention(s)	11 Negative mention(s)	6 Very Negative mention(s)	Neutral

Pfizer has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market. Comparatively, Novo Nordisk A/S has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market.

Pfizer presently has a consensus target price of $28.28, indicating a potential upside of 4.48%. Novo Nordisk A/S has a consensus target price of $65.81, indicating a potential upside of 39.42%. Given Novo Nordisk A/S's higher possible upside, analysts clearly believe Novo Nordisk A/S is more favorable than Pfizer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pfizer	2 Sell rating(s)	14 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.19
Novo Nordisk A/S	1 Sell rating(s)	15 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.19

68.4% of Pfizer shares are owned by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are owned by institutional investors. 0.6% of Pfizer shares are owned by insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Pfizer pays an annual dividend of $1.72 per share and has a dividend yield of 6.4%. Novo Nordisk A/S pays an annual dividend of $1.75 per share and has a dividend yield of 3.7%. Pfizer pays out 226.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Novo Nordisk A/S pays out 42.8% of its earnings in the form of a dividend. Pfizer has raised its dividend for 16 consecutive years. Pfizer is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Novo Nordisk A/S has lower revenue, but higher earnings than Pfizer. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pfizer	$62.58B	2.47	$7.77B	$0.76	35.61
Novo Nordisk A/S	$46.80B	4.50	$15.51B	$4.09	11.54

Summary

Novo Nordisk A/S beats Pfizer on 11 of the 19 factors compared between the two stocks.

Get Novo Nordisk A/S News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NVO vs. The Competition

Export

Metric	Novo Nordisk A/S	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$210.84B	$11.91B	$7.03B	$24.21B
Dividend Yield	3.70%	2.69%	2.58%	3.69%
P/E Ratio	11.55	788.49	269.93	29.11
Price / Sales	4.50	968.58	650.62	13.92
Price / Cash	10.08	15.12	28.89	19.37
Price / Book	7.17	10.34	11.25	4.91
Net Income	$15.51B	$2.77B	$3.45B	$1.06B
7 Day Performance	0.19%	2.18%	3.67%	1.39%
1 Month Performance	-4.61%	-1.35%	-0.49%	2.37%
1 Year Performance	-7.55%	191.22%	77.44%	20.27%

Novo Nordisk A/S Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NVO Novo Nordisk A/S	4.2512 of 5 stars	$47.23 -0.1%	$65.81 +39.4%	-7.5%	$211.15B	$46.80B	11.56	69,505	Earnings Report Dividend Cut Analyst Revision
JNJ Johnson & Johnson	4.604 of 5 stars	$257.48 +1.0%	$267.48 +3.9%	+49.4%	$620.50B	$94.19B	29.84	138,200	Trending News Insider Trade
MRK Merck & Co., Inc.	4.6232 of 5 stars	$130.82 +2.2%	$134.56 +2.9%	+59.3%	$323.10B	$65.01B	36.85	75,000	Earnings Report Insider Trade
NVS Novartis	2.599 of 5 stars	$155.16 +1.2%	$141.20 -9.0%	+33.9%	$296.07B	$54.53B	23.40	75,267
AZN Astrazeneca	4.7725 of 5 stars	$163.40 +5.0%	$211.00 +29.1%	N/A	$253.42B	$58.74B	24.42	96,100	Ex-Dividend Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:NVO) was last updated on 8/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novo Nordisk A/S (NVO) Competitors

NVO vs. JNJ, MRK, NVS, AZN, and PFE

How does Novo Nordisk A/S compare to Johnson & Johnson?

Summary

How does Novo Nordisk A/S compare to Merck & Co., Inc.?

Summary

How does Novo Nordisk A/S compare to Novartis?

Summary

How does Novo Nordisk A/S compare to Astrazeneca?

Summary

How does Novo Nordisk A/S compare to Pfizer?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVO vs. The Competition

Novo Nordisk A/S Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Novo Nordisk A/S (NVO) Competitors

NVO vs. JNJ, MRK, NVS, AZN, and PFE

How does Novo Nordisk A/S compare to Johnson & Johnson?

Do institutionals & insiders have more ownership in NVO or JNJ?

Which has higher earnings and valuation, NVO or JNJ?

Is NVO or JNJ more profitable?

Which has more volatility and risk, NVO or JNJ?

Is NVO or JNJ a better dividend stock?

Does the media prefer NVO or JNJ?

Do analysts prefer NVO or JNJ?

Summary

How does Novo Nordisk A/S compare to Merck & Co., Inc.?

Which has more risk and volatility, MRK or NVO?

Is MRK or NVO more profitable?

Do institutionals & insiders hold more shares of MRK or NVO?

Does the media prefer MRK or NVO?

Which has higher valuation & earnings, MRK or NVO?

Do analysts rate MRK or NVO?

Is MRK or NVO a better dividend stock?

Summary

How does Novo Nordisk A/S compare to Novartis?

Which has more volatility and risk, NVO or NVS?

Does the media prefer NVO or NVS?

Is NVO or NVS a better dividend stock?

Do analysts recommend NVO or NVS?

Do insiders & institutionals believe in NVO or NVS?

Is NVO or NVS more profitable?

Which has higher earnings and valuation, NVO or NVS?

Summary

How does Novo Nordisk A/S compare to Astrazeneca?

Is AZN or NVO more profitable?

Is AZN or NVO a better dividend stock?

Does the media prefer AZN or NVO?

Do insiders & institutionals have more ownership in AZN or NVO?

Do analysts rate AZN or NVO?

Which has more volatility & risk, AZN or NVO?

Which has better valuation & earnings, AZN or NVO?

Summary

How does Novo Nordisk A/S compare to Pfizer?

Is PFE or NVO more profitable?

Does the media refer more to PFE or NVO?

Which has more volatility and risk, PFE or NVO?

Do analysts rate PFE or NVO?

Do insiders & institutionals have more ownership in PFE or NVO?

Is PFE or NVO a better dividend stock?

Which has preferable valuation and earnings, PFE or NVO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVO vs. The Competition

Novo Nordisk A/S Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools